老年人良性前列腺增生%2f下尿路症状治疗共识.pdf

ÀÏÄêÈËÁ¼ÐÔǰÁÐÏÙÔöÉú/ÏÂÄò·֢״ ÖÎÁƹ²ʶ Öì¸ÕÍõ½¨ҵÍõ¶«ÎĶ­±ÌÈØå¿ÔÚ½ðÕÅÏ黪ÓÚÆÕÁÖ³ÂÏþ´º ÁõÓ×˶ ֣ËÉ°Ø Ǯܿ¾ê ǰ ÑÔ Á¼ÐÔǰÁÐÏÙÔöÉú(benign prostatic hyperplasi a£¬BPH)Êǵ¼ÖÂÀÏÄêÄÐÐÔÅÅÄòÕÏ°­×î³£¼ûµÄһÖÖ Á¼ÐÔ¼²²¡¡£×é֯ѧ±íÏÖΪǰÁÐÏÙ¼äÖʺÍÏÙÌå³É·Ö ÔöÉú£»½âÆÊѧ±íÏÖΪǰÁÐÏÙÌå»ýÔö´ó£»ÁÙ´²֢״ÒÔ ÏÂÄò·֢״(lower urinary tract symptoms, LUTS)ΪÖ÷ºÍÄò¶¯Á¦ѧÉϵİòë׳ö¿Ú¹£×è(blad der outlet obstruction, BOO)[1]¡£ 10. 3760/cma. j. issn. 0254-9026.2011.11. 001 ×÷Õßµ¥λ£º100730 ÎÀÉú²¿±±¾©ҽԺÃÚÄòÍâ¿Æ£¨Öì¸Õ¡¢Íõ½¨ҵ£©£¬ÀÏ ÄêҽѧÑо¿Ëù£¨ÓÚÆÕÁÖ£©£»ɽÎ÷ʡÈËÃñҽԺÃÚÄòÍâ¿Æ£¨Íõ¶«ÎÄ£©£»ËÄ´¨´ó ѧ»ªÎ÷ҽԺÀÏÄêҽѧ¿Æ£¨¶­±ÌÈØ£©£»ÖÐÄÏ´óѧÏæÑŶþҽԺÀÏÄ겡¿Æ£¨å¿ ÔÚ½ð¡¢ÁõÓ×˶£©£»±±¾©´óѧÎâ½×ƽÃÚÄòÍâ¿ÆҽѧÖÐÐı±¾©´óѧÊ׸Öҽ ԺÃÚÄòÍâ¿Æ£¨ÕÅÏ黪£©£»¸£½¨ҽ¿Æ´óѧЭºÍҽԺÉñ¾­ÄÚ¿Æ£¨³ÂÏþ´º£©£»ÉÏ º£»ª¶«ҽԺÀÏÄêҽѧ¿Æ£¨֣ËÉ°Ø£©£»¹ã¶«ʡÈËÃñҽԺÀÏÄêҽѧ¿Æ£¨Ǯܿ ¾ê£© Íò·½Êý¾Ý ȱѪÐÔÄÔ Íò·½Êý¾Ý ֲÎïÖƼÁ Íò·½Êý¾Ý ÊÜÌåÞ× Íò·½Êý¾Ý @@[1]ÕÅÏ黪£¬ÍõÐл·£¬Íõ¸Õ£¬µÈ.Á¼ÐÔǰÁÐÏÙÔöÉúÕï¶ÏÖÎ ÁÆָÄÏ.¼û£ºÄÇÑåȺ£¬Ëï¹â£¬ҶÕÂȺ£¬µÈ.ÖйúÃÚÄò Íâ¿Æ¼²²¡Õï¶ÏÖÎÁÆָÄÏ£¨2009°æ£©.±±¾©£ºÈËÃñÎÀÉú³ö °æÉ磬2009:103-119. @@[2] OelkeM, Bachmann A, Descazeaud A, et al. Guidelines on conservative treatment of non neurogenic male LUTS. European Association of Urology, 2010: 1-38. @@[3] McVary KT, Roehrborn CG, Avins AL, et al. American Urological Association Guideline: Management of benign prostatic hyperplasia (BPH), revised, 2010. American Urological Association. 2010: 1-34. @@[4] Chang DF, Campbell JR. Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg, 2005, 31: 664-673. @@[5] Furbery CD, Wright JT, Davis BR, et al. Major outcomes in high-risk hypertensive patients randomized to angiotensin-coverting enzyme inhibitor or calxiun channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA, 2002, 288: 2981-2997. @@[6] Lowe FC. Coadministration of tamsulosin and three an